We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
- Authors
Saif, M W; Erlichman, C; Dragovich, T; Mendelson, D; Toft, D; Burrows, F; Storgard, C; Von Hoff, D
- Abstract
17-(Allylamino)-17-demethoxygeldanamycin (17-AAG) is a benzoquinone ansamycin that binds to and inhibits the Hsp90 family of molecular chaperones leading to the proteasomal degradation of client proteins critical in malignant cell proliferation and survival. We have undertaken a Phase 1 trial of CNF1010, an oil-in-water nanoemulsion of 17-AAG.
- Publication
Cancer chemotherapy and pharmacology, 2013, Vol 71, Issue 5, p1345
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-013-2134-9